P^3-MET-REPAIR: Presepsin (sCD14-ST) for Prediction of Perioperative Risk - MET-REPAIR Nested Cohort Study

Sponsor
University Hospital Heidelberg (Other)
Overall Status
Unknown status
CT.gov ID
NCT03489486
Collaborator
European Society of Anaesthesiology (Other)
1,695
1
10.5
161.7

Study Details

Study Description

Brief Summary

Multicentre international prospective cohort study designed to evaluate whether preoperative presepsin (sCD14-ST) is associated with the composite endpoint: all-cause mortality and major adverse cardiovascular or cerebrovascular events (MACCE) after elevated risk non-cardiac surgery. If so:

  1. What is the optimal cut-off for presepsin to predict the composite endpoint all-cause mortality and MACCE?

  2. Does the calculated optimal cut-off improve prediction of the composite endpoint all-cause mortality and MACCE when added to clinical data and established biomarkers?

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Major non-cardiac surgery is still associated with relevant cardiovascular mortality and morbidity. In Europe, in-hospital mortality exceeded 7% in patients with coronary artery disease and in those with congestive heart failure. Within 30 days of non-cardiac surgery procedures, 8% of patients will suffer a major cardiovascular event.

    Immunological processes, increased recruitment and infiltration of innate and adaptive immune cells into atherosclerotic lesions, have been shown to drive perioperative atherosclerotic lesion progression and plaque destabilization and are thought to promote plaque rupture. When classical monocytes are activated to inflammatory non-classical monocytes, the membrane-bound cell surface protein CD14 is released into circulation. In plasma, soluble CD14 (sCD14) is cleaved by lysosomal proteases. The N-terminal 13kDa fragment constitutes sCD14 subtype (sCD14-ST), also called presepsin. Presepsin has been established as a marker for early identification of patients with systemic infections. Recently, presepsin has been proposed as a biomarker for preoperative risk prediction in cardiac surgery. Our preliminary results in a limited number of patients suggest that presepsin is associated with major adverse cardiovascular and cerebrovascular events after non-cardiac surgery as well with all-cause mortality. Presepsin might have a test characteristic superior to conventional risk assessment on the basis of the revised cardiac risk index (RCRI), high-sensitivity cardiac Troponin-T (hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP).

    Preoperative presepsin quantification might help to identify non-cardiac surgery patients prone to experience perioperative major adverse cardiovascular and cerebrovascular events.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1695 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR): a Prospective, Multi-centre Cohort Observational Study- Presepsin (sCD14-ST) for Perioperative Risk Prediction Nested Cohort Study
    Actual Study Start Date :
    Jun 15, 2018
    Anticipated Primary Completion Date :
    Apr 30, 2019
    Anticipated Study Completion Date :
    Apr 30, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Composite of intra- and postoperative in hospital all-cause mortality, non-fatal cardiac arrest, acute myocardial infarction, congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care ≥24h and stroke [at discharge or at day 30 after surgery (whatever comes first)]

      Number of Patients with Composite of intra- and postoperative in hospital all-cause mortality, non-fatal cardiac arrest, acute myocardial infarction, congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care ≥24h and stroke

    Secondary Outcome Measures

    1. Composite of intra- and postoperative in hospital all-cause mortality, non-fatal cardiac arrest, acute myocardial infarction, congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care ≥24h and stroke [30 days]

      Number of Patients with composite of intra- and postoperative in hospital all-cause mortality, non-fatal cardiac arrest, acute myocardial infarction, congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care ≥24h and stroke for patients recruited in centers conducting 30-day follow-up

    2. All-cause mortality [30 days]

      Number of patients that die of any cause

    3. Non-fatal cardiac arrest [30 days]

      Number of patients with non-fatal cardiac arrest

    4. Myocardial infarction [30 days]

      Number of patients with myocardial infarction

    5. Congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care (≥24h) [30 days]

      Number of patients with congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care (≥24h)

    6. Stroke [30 days]

      Number of patients with stroke

    7. Cardiovascular mortality [30 days]

      Number of patients that die of a cardiovascular cause

    8. In-hospital cardiovascular mortality [30 days]

      Number of patients that die in hospital of a cardiovascular cause

    9. Complications ≥ 3 in Clavien Dindo Classification [within 30 days after surgery]

      Number of patients with ≥ 3 complications in Clavien Dindo Classification

    10. Length of Hospital stay [within 30 days after surgery]

      Number of days participants stayed in hospital

    11. Length of ICU stay [within 30 days after surgery]

      Number of days participants stayed in ICU

    12. Myocardial injury after non-cardiac surgery (MINS) [within 30 days after surgery]

      Number of Patients with MINS

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    45 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:
    • Enrollment in MET-REPAIR (NCT03016936)

    • Signed written informed consent

    No exclusion criteria

    I

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Anaesthesiology, University Hospital Heidelberg Heidelberg Baden-Württemberg Germany 69120

    Sponsors and Collaborators

    • University Hospital Heidelberg
    • European Society of Anaesthesiology

    Investigators

    • Principal Investigator: Jan Larmann, MD/PhD, Department of Anesthesiology, Univeristy Hospital Heidelberg

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jan Larmann, Dr., PhD, University Hospital Heidelberg
    ClinicalTrials.gov Identifier:
    NCT03489486
    Other Study ID Numbers:
    • MET-REPAIR PRESEPSIN
    First Posted:
    Apr 5, 2018
    Last Update Posted:
    Sep 25, 2018
    Last Verified:
    Sep 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jan Larmann, Dr., PhD, University Hospital Heidelberg

    Study Results

    No Results Posted as of Sep 25, 2018